Résumés
Résumé
Les traitements antirétroviraux de l’infection par le VIH sont responsables d’effets secondaires parfois sévères qui touchent en priorité le tissu adipeux, modifiant sa localisation (lipodystrophie avec lipoatrophie périphérique et hypertrophie centrale) et les paramètres du métabolisme glucido-lipidique (dyslipidémie, diabète). Les deux principales classes thérapeutiques, inhibiteurs de protéase et analogues nucléosidiques, sont délétères sur ces paramètres par des mécanismes différents mais qui convergent sur le tissu adipeux. Certaines des molécules de ces deux classes modifient profondément sa différenciation, son métabolisme, sa fonction mitochondriale et l’équilibre des hormones (leptine, adiponectine) et cytokines (TNFα, IL-6) qu’il sécrète. Ce syndrome de lipodystrophie induit un risque cardiovasculaire et de stéatohépatite grevant le pronostic vital. Le traitement reste difficile chez les patients atteints et privilégie le remplacement des molécules les plus délétères par des molécules antirétrovirales plus récentes et moins agressives sur le tissu adipeux.
Summary
HIV infection requires the continuous administration of antiretroviral molecules. Individual molecules belonging to the two main classes, protease inhibitors (PIs) and nucleoside analogues inhibitors of the viral reverse transcriptase (NRTIs) have been shown to be involved in deleterious side effects collectively called the lipodystrophy syndrome. This syndrome associates altered body fat repartition (peripheral lipoatrophy and visceral fat hypertrophy) and metabolic alterations (dyslipidemia, insulin resistance and diabetes). The pathophysiology of these alterations is complex but different studies argue for adipose tissue being a target of some PIs and NRTIs acting through different mechanisms. NRTIs are able to induce mitochondrial dysfonction and to modify adipocyte phenotype and adipose tissue pattern of secretion of cytokines (TNFα, IL-6) and other adipokines (adiponectin, leptin) probably through the production of reactive oxygen species. Some PIs also act on adipocyte, alter its differentiation and insulin sensitivity and also the pattern of secretion of adipokines by adipose tissue. These hypotheses could explain the loss of adipose tissue, while the mechanisms of visceral fat hypertrophy remain speculative. Since some adipokines and the free fatty acids released by adipocytes play a major role in the control of liver and muscles insulin sensitivity, these alterations are probably involved in the metabolic alterations seen in the patients. In addition, lipodystrophic adipose tissue could be involved in the increased lesions of atherogenesis and steatohepatitis presented by these patients. The treatment of lipodystrophy remains difficult and, at present, privileges the switch of the more deleterious drugs towards new molecules less aggressive for adipose tissue.
Parties annexes
Références
- 1. Dworkin MS, Williamson JM. Adult/adolescent spectrum of HIV disease project. AIDS wasting syndrome : trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndr 2003 ; 33 : 267-73.
- 2. Jain RG, Furfine ES, Pedneault L, et al. Metabolic complications associated with antiretroviral therapy. Antiviral Res 2001 ; 51 : 151-77.
- 3. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005 ; 352 : 48-62.
- 4. Mattison RE, Jensen M. The adipocyte as an endocrine cell. Curr Opin EndocrinolDiabetes 2003 ; 10 : 317-21.
- 5. Gougeon ML, Penicaud L, Fromenty B, et al. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 2004 ; 9 : 161-77.
- 6. Nolan D, Mallal S. Complications associated with NRTI therapy : update on clinical features and possible pathogenic mechanisms. Antivir Ther 2004 ; 9 : 849-63.
- 7. Caron M, Auclair M, Lagathu C, et al. HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004 ; 18 : 2127-36.
- 8. Lagathu C, Bastard JP, Auclair M, et al. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 2004 ; 9 : 911-20.
- 9. Lagathu C, Kim M, Maachi M, et al. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 2005 ; 87 : 65-71.
- 10. Mallon PW, Unemori P, Sedwell R, et al.In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005 ; 191 : 1686-96.
- 11. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000 ; 275 : 41325-32.
- 12. Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001 ; 50 : 1378-88.
- 13. Caron M, Auclair M, Sterlingot H, et al. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003 ; 17 : 2437-44.
- 14. Vigouroux C. Laminopathies : lipodystrophies, insulin resistance, syndromes of accelerated ageing… and others. Ann Endocrinol (Paris) 2005 ; 66 : 270-8.
- 15. Liu B, Wang J, Chan KM, et al. Genomic instability in laminopathy-based premature aging. Nat Med 2005 ; 11 : 780-5.
- 16. Varela I, Cadinanos J, Pendas AM, et al. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature 2005 ; 437 : 564-8.
- 17. Hadri KE, Glorian M, Monsempes C, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem 2004 ; 279 : 15130-41.
- 18. McComsey GA, Ward DJ, Hessenthaler SM, et al. Trial to assess the regression of hyperlactatemia and to evaluate the regression of established lipodystrophy in HIV-1-positive subjects (TARHEEL ; ESS40010) study team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine : the results of the TARHEEL study. Clin Infect Dis 2004 ; 38 : 263-70.
- 19. Martin A, Smith DE, Carr A, et al. Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir : the MITOX Extension Study. AIDS 2004 ; 18 : 1029-36.
- 20. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999 ; 13 : 2261-7.
- 21. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003 ; 17 : 1329-38.
- 22. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004 ; 9 : 555-64.
- 23. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003 ; 112 : 1796-808.
- 24. Cancello R, Henegar C, Viguerie N, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005 ; 54 : 2277-86.
- 25. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002 ; 359 : 1026-31.
- 26. Hammond E, Nolan D, McKinnon E, et al. Assessing the contribution of ART, HIV and host factors to changes occurring in adipose tissue of HIV-infected individuals : risk profile for lipoatrophy. Antivir Ther 2005 ; 10(suppl 3) : L4.
- 27. Stulnig TM, Waldhausl W. 11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes. Diabetologia 2004 ; 47 : 1-11.
- 28. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells : the roles of glucocorticoids and 11b-hydroxysteroid dehydrogenase. J Clin Endocrinol Metab 1999 ; 140 : 3189-96.
- 29. Bazuine M, Carlotti F, Tafrechi RS, et al. Mitogen-activated protein kinase (MAPK) phosphatase-1 and -4 attenuate p38 MAPK during dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 2004 ; 18 : 1697-707.
- 30. Degawa-Yamauchi M, Moss KA, Bovenkerk JE, et al. Regulation of adiponectin expression in human adipocytes : effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes Res 2005 ; 13 : 662-9.
- 31. Trujillo ME, Lee MJ, Sullivan S, et al. Tumor necrosis factor (alpha) and glucocorticoid synergistically increase leptin production in human adipose tissue : role for p38 MAPK. J Clin Endocrinol Metab 2006 ; 10 janvier : online.